NCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
Clinical Trials
4 trialsNCT02794337 2022-04-27
TACE-SBRT
Tata Memorial Hospital
Phase 2/3 Unknown
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown
NCT01747642 2012-12-12
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Clinical Research Organization, Dhaka, Bangladesh
Phase 2/3 Unknown